Почетна › Hronična limfocitna leukemija › Arizona
Kliničke studije za Hronična limfocitna leukemija u državi Arizona
15 studija za Hronična limfocitna leukemija traži učesnike na lokacijama u državi Arizona.
Gradovi u državi Arizona
Zvanični tekst studije (na engleskom)
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 118, Bullhead City
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT05645107Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04269902A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Ironwood Cancer & Research Centers, Chandler
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06588478A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Arizona Oncology Associates, P.C. - HOPE, Tucson
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07218341Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kingman Regional Medical Center, Kingman
- Cancer Center at Saint Joseph's, Phoenix
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Banner MD Anderson Cancer Center, Phoenix
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07221500Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Arizona, Scottsdale
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT03516617A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Banner MD Anderson Cancer Center ( Site 0059), Gilbert
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051), Phoenix
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Honor Health Research Institute, Scottsdale
- University of Arizona Cancer Center, Tucson
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Phoenix, Phoenix
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT06973187Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Phoenix, Goodyear
- Mayo Clinic, Phoenix
- Honor Health, Scottsdale
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 3. 9. 2026. · NCT04588922The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Mayo Clinic in Arizona, Scottsdale
Тражи се учесникЗдраве особе су добродошле
Узраст од 18 до 80 · Оба пола · Ажурирано 9. 4. 2026. · NCT05876923A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Arizona Oncology - Tucson - Rudasill /ID# 267552, Tucson
- Southern VA Health Care System /ID# 266254, Tucson
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 4. 2026. · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Banner Health - MD Anderson Cancer Center, Gilbert
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 2. 2026. · NCT05544019Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Arizona, Scottsdale
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 10. 2025. · NCT06712810Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.